Covid-19: Total 8 vaccine candidates are in clinical trial stage, says WHO

On Saturday, Chinese health official, Zhang Wenhong said a successful vaccine against the coronavirus can be administered to humans as early as March in 2021.

The DRDO has developed more than 50 products in the last three-four months to fight the Covid-19 pandemic
As things stand, several countries like the US, and China have even announced tentative dates by when they plan to get a vaccine ready
ANI
2 min read Last Updated : May 17 2020 | 9:38 AM IST
A total of eight vaccine candidates for Covid-19 are in the clinical trial while another 110 are in various stages of development across the globe, according to World Health Organisation (WHO) data.

As governments around the world scramble to curb the contagion, pharmaceutical companies and health institutes in countries like United States, China, and Germany are leading the development to combat the virus, South China Morning Post reported.

As things stand, several countries like the US, and China have even announced tentative dates by when they plan to get a vaccine ready.

On Saturday, Chinese health official, Zhang Wenhong said a successful vaccine against the coronavirus can be administered to humans as early as March in 2021.


"There are uncertainties in developing vaccines. Coronaviruses, including MERS and SARS, have not seen a particularly reliable one so far... the best scenario is that if one of the vaccines that people are making is effective and progressing relatively fast, it should be available as soon as possible from March to June next year," Zhang was quoted by the Global Times.

Earlier, US President Donald Trump had expressed confidence that a vaccine for coronavirus could be available by the end of the year.

"I think we'll have a vaccine by the end of the year," Trump said at a Fox News virtual town hall. "We'll have a vaccine much sooner rather than later."

As the world leaders continue to expedite the date of vaccine, COVID-19 continues to affect the world with over 4.6 million affected with the virus and more than 311,425 deaths.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusWorld Health Organizationhealth care

Next Story